Presented by Álvaro Enríquez García, Advisor Research, Eli Lilly

Session Panellists:

Wilfried Braje, Research Fellow, AbbVie

Yi Yang, Principal Scientist, Ferring Pharmaceuticals 

• Overcoming sustainability challenges in tides synthesis & purification
• Green & organic solvents
• Benchmarking sustainable green chemistry
• Sustainable drug development & manufacturing

Presented by Jean Ge Patent, Attorney at Wolf Greenfield and Li Feng, Partner at Finnegan Henderson Farabow Garrett & Dunner, LLP

A discussion on the importance of a strong patent portfolio for ADC with emphasis on the value of patents that can withstand challenge. There is a need to have a holistic strategy from the outset that takes into consideration not only just obtaining patents, but also using patents to block competitors or generics, and defending the patents when challenged.  

Part I - Prosecution and Patent Strategy, Led by Jean Ge, Patent Attorney at Wolf Greenfield. 

• Worldwide patent portfolio strategy 
  - Timing of filing
  - Scope of disclosure
  - Common traps in a complex patent portfolio
  - Jurisdictional differences  
• Life cycle management – align with regulatory exclusivity and maximize patent exclusivity 

Part II – ADC Patent Litigation and Post Grant Challenge, Led by Li Feng, Partner at Finnegan Henderson Farabow Garrett & Dunner, LLP

• Competitor litigation 
• Biosimilar litigation 
• Interplay between litigation and post-grant challenge 
• Review of ADC patent disputes
• ADC patent litigation and post grant challenge  
• Followed by a recent Amgen case on scope of enablement and impact of ability to obtain broad claims for ADC in the US 

• The use of AI/ML for antibody engineering
• Novel display technologies
• Computational and analytical tools

• Emerging strategies & novel approaches

• Proteomic & bioinformatic technologies

• Improving penetrability for solid tumours
  
  
  

• New tools for immunogenicity profiling

• Immunogenicity of new modalities

• Implementing immunogenicity testing earlier in drug development pipelines

• Challenges in oral delivery of peptides

• Drug formulation strategies

• Future outlook

• Rapid screening analytical methods for oligonucleotides

• Computational approaches, methods & tools

• In vitro and in vivo imaging

• Challenges with targeting solid tumours

• Approaches to activating immune response "cold" tumours

• Therapeutic modalities currently in development showing promise in solid indications